WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
45.69%
Industry
23.86%
Market
117.74%
NVO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NVO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NVO's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
28.21%
Industry
81.22%
Market
15.02%
NVO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NVO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NVO's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NVO earnings and revenue history

Current Revenue
$35.3B
Current Earnings
$12.9B
Current Profit Margin
36.6%

NVO Return on Equity

Current Company
91.8%
Current Industry
20.6%
Current Market
28.2%
NVO's Return on Equity (91.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NVO announces earnings.

NVO Return on Assets

Current Company
29.9%
Current Industry
5%
NVO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NVO Return on Capital Employed

Current Company
84.19%
Current Industry
-42.5%
NVO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NVO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NVO$35.14B$17.67B$12.85B+15.46%+19.19%
VRTX$10.19B$5.01B$4.02B+25.55%+12.96%
REGN$13.10B$4.55B$3.86B+21.21%+9.99%
MRNA$5.15B-$4.22B-$5.97B+111.40%N/A
BNTX$2.94B$397.96M$121.51M+121.89%-96.92%
View Top Biotech Stocks

Novo Nordisk A S Earnings & Revenue FAQ

What were NVO's earnings last quarter?

On Invalid Date, Novo Nordisk A S (NYSE: NVO) reported Q1 2024 earnings per share (EPS) of $0.83, up 28.11% year over year. Total Novo Nordisk A S earnings for the quarter were $3.68 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.64.

If you're new to stock investing, here's how to buy Novo Nordisk A S stock.

What was NVO's earnings growth in the past year?

As of Q2 2024, Novo Nordisk A S's earnings has grown 45.69% year over year. This is 21.83 percentage points higher than the US Biotechnology industry earnings growth rate of 23.86%. Novo Nordisk A S's earnings in the past year totalled $12.85 billion.

What was NVO's revenue last quarter?

On Invalid Date, Novo Nordisk A S (NYSE: NVO) reported Q1 2024 revenue of $9.46 billion up 21.03% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $7.81 billion.

What was NVO's revenue growth in the past year?

As of Q2 2024, Novo Nordisk A S's revenue has grown 28.21% year over year. This is 53.01 percentage points lower than the US Biotechnology industry revenue growth rate of 81.22%. Novo Nordisk A S's revenue in the past year totalled $35.14 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.